CN111989087A - 用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒 - Google Patents

用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒 Download PDF

Info

Publication number
CN111989087A
CN111989087A CN201980022079.9A CN201980022079A CN111989087A CN 111989087 A CN111989087 A CN 111989087A CN 201980022079 A CN201980022079 A CN 201980022079A CN 111989087 A CN111989087 A CN 111989087A
Authority
CN
China
Prior art keywords
cbz
nps
pebca
drug delivery
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980022079.9A
Other languages
English (en)
Chinese (zh)
Inventor
Y·马尔奇
R·施密德
E·苏尔海姆
P·斯坦斯特德
H·约翰森
K·山特维克
G·莫兰斯莫
T·苏格兰
K·弗莱特马克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oslo National Hospital, University of
Xintai Futuote Co ltd
Original Assignee
Oslo National Hospital, University of
Xintai Futuote Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oslo National Hospital, University of, Xintai Futuote Co ltd filed Critical Oslo National Hospital, University of
Publication of CN111989087A publication Critical patent/CN111989087A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980022079.9A 2018-03-27 2019-03-27 用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒 Pending CN111989087A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20180429 2018-03-27
NO20180429 2018-03-27
PCT/EP2019/057678 WO2019185685A1 (en) 2018-03-27 2019-03-27 Poly (alkyl cyanoacrylate) nanoparticles for use in treatment of cancer

Publications (1)

Publication Number Publication Date
CN111989087A true CN111989087A (zh) 2020-11-24

Family

ID=66049182

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980022079.9A Pending CN111989087A (zh) 2018-03-27 2019-03-27 用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒
CN201980096306.2A Pending CN113840594A (zh) 2018-03-27 2019-09-26 用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980096306.2A Pending CN113840594A (zh) 2018-03-27 2019-09-26 用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒

Country Status (8)

Country Link
US (3) US20210113482A1 (cg-RX-API-DMAC7.html)
EP (2) EP3773471A1 (cg-RX-API-DMAC7.html)
JP (2) JP7317038B2 (cg-RX-API-DMAC7.html)
CN (2) CN111989087A (cg-RX-API-DMAC7.html)
AU (1) AU2019437385B2 (cg-RX-API-DMAC7.html)
BR (2) BR112020019452A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134923A1 (cg-RX-API-DMAC7.html)
WO (2) WO2019185685A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12433846B2 (en) 2019-03-27 2025-10-07 Sintef Tto As Drug delivery system for treatment of cancer
CN111989087A (zh) 2018-03-27 2020-11-24 新泰福托特股份有限公司 用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒
JP7461932B2 (ja) * 2018-08-23 2024-04-04 シンテフ ティーティーオー エイエス ナノ粒子
KR20230031188A (ko) * 2020-02-26 2023-03-07 바이오써젠 에이에스 치료적 폴리엔 마크롤리드의 제약 조성물 및 그의 사용 방법
GB202501169D0 (en) 2025-01-27 2025-03-12 Sintef Tto As Methods of producing polymeric particles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102159190A (zh) * 2008-08-06 2011-08-17 生物联盟制药公司 化疗剂的口服制剂
EP2508207A1 (en) * 2011-03-31 2012-10-10 BioAlliance Pharma Nanoparticles loaded with chemotherapeutic antitumoral Drug
CN105518031A (zh) * 2013-05-28 2016-04-20 挪威科技工业研究院Tto股份公司 用于制备隐形纳米颗粒的方法
CN107115532A (zh) * 2016-02-24 2017-09-01 首都医科大学宣武医院 一种双重修饰聚氰基丙烯酸正丁酯纳米粒、其制备方法及用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2872703B1 (fr) 2004-07-07 2006-10-06 Ethypharm Sa Nanoparticules polymeriques composites
JP2008542293A (ja) 2005-05-23 2008-11-27 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 超音波増強ナノ粒子媒介性薬物送達のためのエコー形成性マイクロバブルおよびマイクロエマルジョン
EP1876188A1 (en) 2006-07-04 2008-01-09 NanoDel Technologies GmbH Two step miniemulsion process
US8679539B2 (en) * 2007-01-31 2014-03-25 Tong Shen Enterprise Co., Ltd. Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof
FR2921660B1 (fr) 2007-10-01 2015-09-25 Centre Nat Rech Scient Nanoparticules hybrides organiques inorganiques a base de carboxylates de fer.
US20150343079A1 (en) 2012-10-25 2015-12-03 Sogang University Research Foundation Ultrasound contrast agent with nanoparticles including drug and method for preparing the same
US10391185B2 (en) 2014-11-26 2019-08-27 Fujifilm Visualsonics, Inc. Multimodal ultrasound and photoacoustic contrast agent based on polymeric microparticles
WO2016134115A1 (en) 2015-02-20 2016-08-25 Trustees Of Boston University Theranostic compositions and uses thereof
EP3316871A4 (en) * 2015-06-30 2019-02-20 The Trustees of Columbia University in the City of New York TALKED COMPOSITION AND USES THEREOF
US20170071866A1 (en) * 2015-09-14 2017-03-16 Onxeo S.A. Nanoparticles loaded with active ingredients, their process of preparation, and their uses
WO2017046037A1 (en) * 2015-09-14 2017-03-23 Onxeo Nanoparticles loaded with active ingredients, their process of preparation and their uses
US10980826B2 (en) * 2015-11-06 2021-04-20 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
KR102803158B1 (ko) * 2015-12-02 2025-05-08 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
KR20170133257A (ko) 2016-05-24 2017-12-05 한양대학교 산학협력단 항암제 함유 나노입자를 포함하는 뇌질환 치료를 위한 비강 투여용 약제학적 조성물
EP3518900A1 (en) 2016-09-29 2019-08-07 Sintef TTO AS A new drug delivery system for treatment of disease
NO342271B1 (en) 2016-09-29 2018-04-30 Sintef Tto As A new drug delivery system for treatment of cancer
CN111989087A (zh) * 2018-03-27 2020-11-24 新泰福托特股份有限公司 用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒
US12433846B2 (en) 2019-03-27 2025-10-07 Sintef Tto As Drug delivery system for treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102159190A (zh) * 2008-08-06 2011-08-17 生物联盟制药公司 化疗剂的口服制剂
EP2508207A1 (en) * 2011-03-31 2012-10-10 BioAlliance Pharma Nanoparticles loaded with chemotherapeutic antitumoral Drug
CN105518031A (zh) * 2013-05-28 2016-04-20 挪威科技工业研究院Tto股份公司 用于制备隐形纳米颗粒的方法
CN107115532A (zh) * 2016-02-24 2017-09-01 首都医科大学宣武医院 一种双重修饰聚氰基丙烯酸正丁酯纳米粒、其制备方法及用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SNIPSTAD S等: "Ultrasound improves the delivery and therapeutic effect of nanoparticle-stabilized microbubbles in breast cancer xenografts", 《ULTRASOUND IN MEDICINE & BIOLOGY》 *

Also Published As

Publication number Publication date
BR112020019452A2 (pt) 2021-01-05
JP7550167B2 (ja) 2024-09-12
US20200061019A1 (en) 2020-02-27
JP7317038B2 (ja) 2023-07-28
EP3946253A1 (en) 2022-02-09
WO2019185685A1 (en) 2019-10-03
US11806330B2 (en) 2023-11-07
EP3773471A1 (en) 2021-02-17
US20190298682A1 (en) 2019-10-03
AU2019437385A1 (en) 2021-11-04
AU2019437385B2 (en) 2025-04-10
JP2022527858A (ja) 2022-06-06
WO2020192950A1 (en) 2020-10-01
US20210113482A1 (en) 2021-04-22
CA3134923A1 (en) 2020-10-01
CN113840594A (zh) 2021-12-24
JP2021519323A (ja) 2021-08-10
BR112021019003A2 (pt) 2021-11-30

Similar Documents

Publication Publication Date Title
Chen et al. Anti prostate cancer therapy: aptamer-functionalized, curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles
Fusser et al. Cabazitaxel-loaded Poly (2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
Pei et al. ROS-sensitive thioketal-linked polyphosphoester-doxorubicin conjugate for precise phototriggered locoregional chemotherapy
Song et al. Erythrocyte-biomimetic nanosystems to improve antitumor effects of paclitaxel on epithelial cancers
Wang et al. pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma
Mugundhan et al. Nanoscale strides: exploring innovative therapies for breast cancer treatment
Dai et al. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer
JP7317038B2 (ja) がん治療に使用するためのポリ(アルキルシアノアクリレート)ナノ粒子
Wang et al. Enhanced anti-colon cancer efficacy of 5-fluorouracil by epigallocatechin-3-gallate co-loaded in wheat germ agglutinin-conjugated nanoparticles
Xu et al. Enhancing the efficacy and safety of doxorubicin against hepatocellular carcinoma through a modular assembly approach: the combination of polymeric prodrug design, nanoparticle encapsulation, and cancer cell-specific drug targeting
Zhang et al. Multifunctional polyethylene glycol (PEG)-poly (lactic-co-glycolic acid)(PLGA)-based nanoparticles loading doxorubicin and tetrahydrocurcumin for combined chemoradiotherapy of glioma
Zhang et al. Tumor-targeting micelles based on linear–dendritic PEG–PTX8 conjugate for triple negative breast cancer therapy
Xu et al. Transferrin and tocopheryl-polyethylene glycol-succinate dual ligands decorated, cisplatin loaded nano-sized system for the treatment of lung cancer
Behl et al. Nano-based drug delivery of anticancer chemotherapeutic drugs targeting breast cancer
Cai et al. Multifunctional pH-responsive folate receptor mediated polymer nanoparticles for drug delivery
US20140296173A1 (en) Stable nanocomposition comprising epirubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it
Rathod et al. Nano‐curcumin for cancer therapy: A strategic approach to improve bioavailability and modulate tumor resistance
Guo et al. Anti-neoangiogenic nanodelivery systems: advances in tumor-based and ophthalmic disease research
Li et al. GGT and GSH-triggered nanoplatform for efficient gambogic acid delivery and tumor penetration in triple-negative breast cancer
US12433846B2 (en) Drug delivery system for treatment of cancer
Patnala et al. Nanotechnology advances in breast cancer
Singh et al. Ligand-mediated targeted drug delivery approaches against hepatocellular carcinoma
Alavi et al. Nanocarrier system for increasing the therapeutic efficacy of oxaliplatin
Shree et al. Current insights into polymeric nanocarriers for delivery of phytomedicines in breast cancer therapy
Shen et al. Highly permeable and tumor-selective killing Doxil for efficient cancer therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination